CSCI
COSCIENS Biopharma Inc
$
4.330
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.400
Open
4.075
VWAP
4.19
Vol
10.32K
Mkt Cap
13.62M
Low
4.0104
Amount
43.20K
EV/EBITDA(TTM)
--
Total Shares
3.15M
EV
1.74M
EV/OCF(TTM)
--
P/S(TTM)
1.11
COSCIENS Biopharma Inc. is a Canada-based life science company. The Company is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The Company's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
Show More
Valuation Metrics
The current forward P/E ratio for COSCIENS Biopharma Inc (CSCI.O) is 0.24, compared to its 5-year average forward P/E of -3.15. For a more detailed relative valuation and DCF analysis to assess COSCIENS Biopharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.15
Current PE
0.24
Overvalued PE
2.41
Undervalued PE
-8.70
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.08
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.40
Undervalued EV/EBITDA
-0.23
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
10.04
Current PS
0.89
Overvalued PS
25.17
Undervalued PS
-5.08
Financials
Annual
Quarterly
FY2025Q1
YoY :
+37400.00%
1.50M
Total Revenue
FY2025Q1
YoY :
-40.80%
-3.62M
Operating Profit
FY2025Q1
YoY :
-36.46%
-3.66M
Net Income after Tax
FY2025Q1
YoY :
-75.53%
-1.16
EPS - Diluted
FY2025Q1
YoY :
-41.91%
-2.50M
Free Cash Flow
FY2025Q1
YoY :
-109.84%
29.53
Gross Profit Margin - %
FY2025Q1
YoY :
+78.40%
-125.68
FCF Margin - %
FY2025Q1
YoY :
-99.83%
-243.67
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CSCI News & Events
Events Timeline
2025-05-26 (ET)
2025-05-26
07:46:02
Cosciens Biopharma announces receipt of Goodwood intended director nominations
2025-04-14 (ET)
2025-04-14
07:11:52
Cosciens Biopharma appoints Biehn as CEO
2025-03-19 (ET)
2025-03-19
19:04:37
Cosciens Biopharma announces possible delay in filing 2024-end documents
Sign Up For More Events
Sign Up For More Events
News
9.0
05-30NewsfilterCOSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders
5.0
05-30SeekingAlphaCOSCIENS Biopharma reconstitutes board
9.5
05-13NewsfilterCOSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Sign Up For More News
People Also Watch
ADGM
Adagio Medical Holdings Inc
1.400
USD
-6.67%
IVDA
Iveda Solutions Inc
2.240
USD
-9.31%
SGLY
Singularity Future Technology Ltd
1.060
USD
-1.85%
MNDR
Mobile-health Network Solutions
1.061
USD
-0.84%
ASTC
Astrotech Corp
5.508
USD
-3.37%
BCLI
Brainstorm Cell Therapeutics Inc
0
USD
-2.56%
RDIB
Reading International Inc
9.030
USD
-3.42%
YQ
17 Education & Technology Group Inc
2.213
USD
-8.17%
VINE
Fresh Vine Wine Inc
0
USD
+10.78%
MYNA
Mynaric AG
0
USD
-61.26%
FAQ
What is COSCIENS Biopharma Inc (CSCI) stock price today?
The current price of CSCI is 4.33 USD — it has increased 5.61 % in the last trading day.
What is COSCIENS Biopharma Inc (CSCI)'s business?
What is the price predicton of CSCI Stock?
What is COSCIENS Biopharma Inc (CSCI)'s revenue for the last quarter?
What is COSCIENS Biopharma Inc (CSCI)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for COSCIENS Biopharma Inc (CSCI)'s fundamentals?
How many employees does COSCIENS Biopharma Inc (CSCI). have?